CONFLICT OF INTEREST DISCLOSURE
Mahendra Joshi and Shivkumar Madki are Directors of IDRS Labs Pvt. Ltd.
with financial interest in the product. Dr. Archana Khosa Kakkar is an
employee of IDRS Labs Pvt. Ltd. and has financial interest in the
product. The remaining authors have no relevant conflicts of interest to
declare.
- Sharma H, Wadhwa R. Mercaptopurine. In: StatPearls . StatPearls
Publishing; 2022. Accessed December 9, 2022.http://www.ncbi.nlm.nih.gov/books/NBK557620/
- Maintenance therapy for acute lymphoblastic leukemia: basic science
and clinical translations | Leukemia. Accessed December 12,
2022.https://www.nature.com/articles/s41375-022-01591-4
- Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J.
Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute
Lymphoblastic Leukemia: Clinical Facts and Fiction. J Pediatr
Hematol Oncol . 2014;36(7):503-517.
doi:10.1097/MPH.0000000000000206
- Sahasranaman S, Howard D, Roy S. Clinical pharmacology and
pharmacogenetics of thiopurines. Eur J Clin Pharmacol .
2008;64(8):753-767.
doi:10.1007/s00228-008-0478-6
- Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of
oral mercaptopurine. Is maintenance chemotherapy in acute
lymphoblastic leukemia being optimally delivered? N Engl J Med .
1983;308(17):1005-1009.
doi:10.1056/NEJM198304283081705
- Bhatia S, Landier W, Hageman L, et al. High Intra-Individual
Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children
With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse:
Results From a Children’s Oncology Group (COG) Study (AALL03N1).Blood . 2013;122(21):59.
doi:10.1182/blood.V122.21.59.59
- Adam de Beaumais T, Fakhoury M, Medard Y, et al. Determinants of
mercaptopurine toxicity in paediatric acute lymphoblastic leukemia
maintenance therapy. Br J Clin Pharmacol . 2011;71(4):575-584.
doi:10.1111/j.1365-2125.2010.03867.x
- Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and
pharmacodynamics of oral methotrexate and mercaptopurine in children
with lower risk acute lymphoblastic leukemia: a joint children’s
cancer group and pediatric oncology branch study. Blood .
1998;92(10):3569-3577.
- Mulla H, Leary A, White P, Pandya HC. A Step Toward More Accurate
Dosing for Mercaptopurine in Childhood Acute Lymphoblastic Leukemia.The Journal of Clinical Pharmacology . 2012;52(10):1610-1613.
doi:10.1177/0091270011423663
- Vu K, Emberley P, Brown E, et al. Recommendations for the safe use and
handling of oral anticancer drugs in community pharmacy: A
pan-Canadian consensus guideline. Can Pharm J (Ott) .
2018;151(4):240-253.
doi:10.1177/1715163518767942
- Breitkreutz J, Buckham J, Fischer R, Pöstges R, Boos J. Comparative in
vitro studies on different 6-mercaptopurine formulations for use in
children. Paediatric and Perinatal Drug Therapy. 2007;8:31-39.
doi:10.1185/146300907X167817
- Hawwa AF, Collier PS, Millership JS, et al. Population pharmacokinetic
and pharmacogenetic analysis of 6-mercaptopurine in paediatric
patients with acute lymphoblastic leukaemia. Br J Clin
Pharmacol . 2008;66(6):826-837.
doi:10.1111/j.1365-2125.2008.03281.x
- Lennard L. Therapeutic drug monitoring of cytotoxic drugs.British Journal of Clinical Pharmacology . 2001;52(S1):75-87.
doi:10.1111/j.1365-2125.2001.00366.x
- Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J. Metabolites of
mercaptopurine in red blood cells: a relationship between
6-thioguanine nucleotides and 6-methylmercaptopurine metabolite
concentrations in children with lymphoblastic leukemia. Eur J
Pharm Sci . 1999;8(4):329-334.
doi:10.1016/s0928-0987(99)00027-5
- Rosdiana DS, Setiabudy R, Andalusia R, et al. TPMT Genetic Variability
and Its Association with Hematotoxicity in Indonesian Children with
Acute Lymphoblastic Leukemia in Maintenance Therapy.Pharmgenomics Pers Med . 2021;14:199-210.
doi:10.2147/PGPM.S288988
- Bhatia S, Landier W, Hageman L, et al. Systemic Exposure to
Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic
Leukemia: A Children’s Oncology Group Study. JAMA Oncol .
2015;1(3):287-295.
doi:10.1001/jamaoncol.2015.0245
- Zhou Y, Wang L, Zhai XY, et al. Precision therapy of 6-mercaptopurine
in Chinese children with acute lymphoblastic leukaemia. Br J
Clin Pharmacol . 2020;86(8):1519-1527.
doi:10.1111/bcp.14258
- Maintenance therapy of childhood acute lymphoblastic leukemia
revisited—Should drug doses be adjusted by white blood cell,
neutrophil, or lymphocyte counts? - Schmiegelow - 2016 - Pediatric
Blood & Cancer - Wiley Online Library. Accessed December 15, 2022.https://onlinelibrary.wiley.com/doi/10.1002/pbc.26139
- The Seventh International Childhood Acute Lymphoblastic Leukemia
Workshop Report: Palermo, Italy, January 29–30, 2005 |
Leukemia. Accessed December 15, 2022.https://www.nature.com/articles/2403783
- Tolbert JA, Bai S, Abdel-Rahman SM, et al. Pharmacokinetics of two
6-mercaptopurine liquid formulations in children with acute
lymphoblastic leukemia. Pediatr Blood Cancer . 2017;64(8).
doi:10.1002/pbc.26465
- Larsen RH, Hjalgrim LL, Grell K, et al. Pharmacokinetics of tablet and
liquid formulations of oral 6-mercaptopurine in children with acute
lymphoblastic leukemia. Cancer Chemother Pharmacol .
2020;86(1):25-32.
doi:10.1007/s00280-020-04097-x
- Mulla H, Leary A, White P, Pandya HC. A step toward more accurate
dosing for mercaptopurine in childhood acute lymphoblastic leukemia. J
Clin Pharmacol. 2012;52(10):1610-1613. doi:10.1177/0091270011423663
- Zhang F, Jia R, Gao H, Wu X, Liu B, Wang H. In Silico Modeling and
Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual
Population. Clin Pharmacokinet . 2021;60(11):1373-1385.
doi:10.1007/s40262-021-01045-7
- Liu T, Ghafoori P, Gobburu JVS. Allometry Is a Reasonable Choice in
Pediatric Drug Development. J Clin Pharmacol .
2017;57(4):469-475.
doi:10.1002/jcph.831
- Mulla H, Buck H, Price L, Parry A, Bell G, Skinner R.
“Acceptability” of a new oral suspension formulation of
mercaptopurine in children with acute lymphoblastic leukaemia. J
Oncol Pharm Pract . 2016;22(3):387-395.
doi:10.1177/1078155215577808Tables